Back to search

Peptide record

TPDB92681

PepFect (PF)14 PepFect 14 PepFect 14 (PF14) PepFect14 (PF14) PF14 Cell-penetrating Peptides modified_plain modified
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92681
PepFect (PF)14 PepFect 14 PepFect 14 (PF14) PepFect14 (PF14) PF14
Cell-penetrating Peptides
Delivery and barrier-penetrating peptides
CPPsite3.0
modified_plain
Yes
A 21-aa modified cell-penetrating peptides peptide sequence curated from CPPsite3.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: Stearylation
Sequence
AGYLLGKLLOOLAAAALOOLL-NH2
Physicochemical Analysis
C82H142N18O19
RNDCEQHIMFPSTWV
L
1684.14
9.74
1
0
14
+1
-5.26
1.590
172.38
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
1490
88.47
1
Residue Composition
number
5
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
0
I
8
L
1
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 5 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 8 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
21
C82H142N18O19
1684.14
9.74
+1
-5.26
1.590
Amidation
Modified
Cationic Amphipathic Cationic and amphipathic
Linear
Stearylation
N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O NCC(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O NCC(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)O N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O
Evidence Records 16 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

BHK-21, HepG2, HEK 293 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Non-natural residues Linear Modified Cationic
Synthetic
Nucleic acid (siRNA )
In vitro
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

HeLa pLuc705 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear Modified Amphipathic
Synthetic
Nucleic acid (Cy5-labeled SCO)
Cytoplasm
Endocytic pathway
In vitro
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Target

SKOV-3 Cells And SKOV-3- GFP/Luc Cells [2D And 3D Tumor Models]

Assay & Model

Xenograft model [Female nude BALB/c mice (BALB/cAnNRj-Foxn1nu/nu] carrying an IP tumor of SKOV-3-GFP/Luc cells
Xenograft model [Female nude BALB/c mice (BALB/cAnNRj-Foxn1nu/nu] carrying an IP tumor of SKOV-3-GFP/Luc cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear Modified Cationic and amphipathic
Synthetic
Cy5-eGFP or mCherry mRNA
Around 33% of the cells incubated with PF14 showed Cy5 fluorescence, whereas this was 12% of the cells incubated with LipMM
In vitro and in vivo
Evidence 4 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Pluc 705 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear Modified Amphipathic
Synthetic
Splice correcting oligonucleotide (PS-20-OMe SCO)
Fold increase in activity over treatment with oligonucleotide alone.
In vitro
Evidence 5 Activity

Activity

Cell-penetrating Peptides

Target

U87-Luc Glioblastoma And Pc12 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear Modified Cationic and amphipathic
Synthetic
Cy5-siRNA
Plasma Membrane
In vitro
Evidence 6 Activity

Activity

Cell-penetrating Peptides

Target

U87 Mg-Luc2 And HeLa-Luc Cell Lines

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear Modified Amphipathic
Synthetic
Double-stranded siRNA luc
Cytosol
PF14:siRNA in complex with and without TGs showed more efficient gene-silencing than PF51 at the same siRNA concentration (25 nM), reaching more than 80% knockdown of luciferase expression in U87 MG-luc2 cells
In vitro
CHHHHHHHHHHHTTSSCGGGCC
Evidence 7 Activity

Activity

Cell-penetrating Peptides

Target

Hes Cell Line H9 (Wa09) And H1 (Wa01)

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear Modified
Alexa Fluor 568 conjugated siRNA
Cytoplasm
Transfection with PF14 complexes for 4 h is sufficient to transfer siRNA into the majority of the hES cells as 91% of live cells appeared to be Alexa Fluor 568-positive
In vitro
CCSCSCCSCSTTHHHHSCC
Evidence 8 Activity

Activity

Cell-penetrating Peptides

Assay & Model

Balb/c mice(8–10 week old)
Balb/c mice(8–10 week old)

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear Modified
Synthetic
siRNA and pDNA encoding shRNA
The lung-to-nonlung transfection ratio is 16 to 350-fold enrichment among the main organs.
In vivo
CCCCCCCC
Evidence 9 Activity

Activity

Cell-penetrating Peptides

Target

Ppc-1 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear Modified
Synthetic
Dy547-labeled microRNA-34a (miR-34a)
Very high levels of miR-34a-5p in PPC-1 cells transfected with PF14:miR-34a-5p and siPORT:miR-34a-5p than control-transfected and untransfected cells
In vitro
CCCSCCCCCCC
Evidence 10 Activity

Activity

Cell-penetrating Peptides

Target

HeLa, HeLa Pluc/705

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear Modified Cationic
Synthetic
Alexa568-labelled SCO
Nucleus And Autolysosomes
In vitro
CCCCSCCCGGGTSCSSSCCGGGGTCTTSSCCCTTSTTHHHHTTCC
Evidence 11 Activity

Activity

Cell-penetrating Peptides

Target

U87 Mg-Luc2

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear Modified Amphipathic
Synthetic
Small interfering RNAs (siRNA)
In vitro
Evidence 12 Activity

Activity

Cell-penetrating Peptides

Target

Keratinocytes (Kcs) And Dendritic Cells (Dcs).

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear Modified Amphipathic
Synthetic
DyLight547-labelled microRNA-146a and siRNA
Multilamellar Vesicles (Mlv)
Caveolae mediated endocytosis
In vitro
CBCCSTHHHHCGGGGTSCSTTBTCCCCC
Evidence 13 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Pluc 705, HeLa Egfp 654, U87 Mg-Luc2

Source & Reference

CPPsite3.0
CPPsite3
PCT/SE2022/050657

Other

Natural residues Linear Modified Cationic and amphipathic
Synthetic
SCO-Cy5
In vitro
CBSSSBCCEETTEECCTTCCCC
Evidence 14 Activity

Activity

Cell-penetrating Peptides

Target

HeLa pLuc705 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear Modified Amphipathic
Synthetic
SR-A3s and SR-A5s & Splice-switching oligonucleotide (SCO)
plasma membrane
Macropinocytosis and caveolae mediated endocytosis
In vitro
Evidence 15 Activity

Activity

Cell-penetrating Peptides

Target

HeLa and U2OS-SAMP1-YFP cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear Modified
Synthetic
plasmid pGL3 and siRNA
Taken up by SCARA efficiently than PF6
In vitro
CCTTHHHHTTTTTTC
Evidence 16 Activity

Activity

Cell-penetrating Peptides

Target

HeLa pLuc705 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear Modified Amphipathic
Synthetic
Alexa 568 labelled SCO
Endosomes or on the cellular membrane
Dose-dependent internalization in presence of MPEP, ciproxifan or VU0357121
Endocytosis
In vitro
CCCCCCCC
Additional Detail Fields 1 fields
CHHHHHHHHHHHTTSSCGGGCC CCSCSCCSCSTTHHHHSCC CCCCCCCC CCCSCCCCCCC CCCCSCCCGGGTSCSSSCCGGGGTCTTSSCCCTTSTTHHHHTTCC CBCCSTHHHHCGGGGTSCSTTBTCCCCC CBSSSBCCEETTEECCTTCCCC CCTTHHHHTTTTTTC